Beauty and the beast.

June 15, 2017. The BELLE-2 trial published this month in Lancet Oncology shows that PI3K inhibition using buparlisib in addition to fulvestrant improves progression-free survival (PFS) in postmenopausal women with aromatase inhibitor-resistant ER(+), HER2(-) breast cancer. 1147 women were randomized to fulvestrant +/- buparlisib with the experimental cohort achieving a significant PFS advantage of 2 months (3 months among patients with known activation of the PI3K pathway). But buparlisib did a number on the liver causing many people to discontinue therapy after very short exposure times. Looks like we still have some work to do before we tame the beast.


Popular Posts